ADMA Biologics (ADMA) Misses Q4 EPS by 11c

ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of ($0.08), $0.11 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $73.9 million versus the consensus estimate of $72.15 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Weibo (WB) Tops Q2 EPS by 2c